Don't miss this issue of The Altascientist
Shortening Drug Development Timelines with Asian Ethnobridging Trials
Developing drugs for the Asian market may require that Phase I studies be repeated in regions outside North America and Europe. Altasciences has the clinical capabilities to demonstrate biosimilarity of drug products between Asian and non-Asian populations by comparing pharmacokinetics of the investigational drug in both ethnic groups, providing a safe strategy to save time and money.
In our latest issue of The Altascientist, using case studies, we discuss how ethnobridging can prevent the necessity of regional-specific development programs, helping you achieve commercial milestones safely and more efficiently.
Download your copy today! Listen to the audio recording!
Speak with an expert today to discuss your next study!
Got a few more minutes? You may also be interested in the following webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.